Neumentum, Inc.
  • About
  • Leadership
  • Pain
    • Chronic Pain
    • Acute Pain
  • Pipeline
    • NTM-001
    • NTM-006
    • Early Stage
  • Investors
  • Media
  • Contact Us
Select Page

Neumentum Enters into Global Licensing Agreement for a Novel Class of Investigational Pain Treatments

by Sky Striar | Oct 10, 2019 | Press Releases

Agreement significantly expands Neumentum’s pipeline of investigational pain therapies aimed at addressing the growing need for innovative analgesics  PALO ALTO, Calif., October 10, 2019 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain...

Neumentum Presents Data on Lead Product Candidate NTM-001 at PAINWeek 2019

by Sky Striar | Sep 5, 2019 | Press Releases

Neumentum’s poster presentations #39, #40, #41 and #42 from PAINWeek are now available to view.   – Results Support What Has the Potential To Be the First-Ever Non-Steroidal Anti-Inflammatory (NSAID) Approved for Continuous Infusion – Results Confirm...

Neumentum Phase I Study Confirms Its Non-Opioid in Development for Moderately Severe Acute Pain, NTM-001, Performs in Healthy Adults as Predicted

by Sky Striar | Jan 7, 2019 | Press Releases

– The Phase I Clinical Study of a Continuously Infused NSAID, NTM-001, Provided Steady Plasma Levels of Ketorolac Over 24 Hours, With No Unexpected Adverse Effects – Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for Continuous Infusion Has the...